A Phase 3, Randomized, Double-Blinded, Placebo-Controlled Study of ARQ 197 Plus Erlotinib Versus Placebo Plus Erlotinib
Status:
Terminated
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to determine if the combination regimen of ARQ 197
with erlotinib will improve overall survival (OS) compared to erlotinib monotherapy in
subjects with locally advanced or metastatic non-squamous NSCLC with wild-type EGFR who have
received 1 or 2 prior systemic anti-cancer therapies in the Intent-to-Treat (ITT) population.